Cadila 'Healthy' and green

Cadila Healthcare announced a good news today morning. It stated that its Oral Solid Dosage drug manufacturing plant located at SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in January 2016.

The receipt of EIR indicates the successful closure of the inspection points (483s) raised. It may be mentioned that this plant is a separate manufacturing unit and does not form a part of the Moraiya formulations manufacturing facility.

And prior to this, a fortnight ago, the company had said that its Topical manufacturing facility located at Changodar, Ahmedabad has received an EIR from the USFDA following the inspection carried out in March 2016.

The receipt of this EIR has been received with cheer by the market, which is otherwise only used to getting US FDA warnings! The stock price is up 2.5% at Rs.385 levels with an intra day high at Rs.391.